Palatin Technologies (PTN) Reports In-Line Q3 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Palatin Technologies (PTN) Reports In-Line Q3 Loss

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on May 17, 2016

May 17, 2016 7:30 AM EDT

CRANBURY, N.J., May 17, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2016. 

Quarter Ended March 31, 2016 and Recent Highlights

Bremelanotide development for Female Sexual Dysfunction (FSD): Palatin's two Phase 3 clinical trials for the treatment of FSD initiated in December 2014 and January 2015 are progressing as planned and meeting target objectives. Patient... More